Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Confirm Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
Sponsor: Hansoh BioMedical R&D Company
Summary
This study has been designed to confirm the clinical efficacy and safety of HS-10374 in the treatment of moderate to severe plaque psoriasis.
Official title: A Multi-Center, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HS-10374 in Adult Subjects With Moderate To Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
375
Start Date
2024-11-04
Completion Date
2026-06-29
Last Updated
2024-11-04
Healthy Volunteers
No
Conditions
Interventions
HS-10374 6mg tablets
Specified dose of HS-10374 tablets administered orally QD on specified days
HS-10374-matched placebo tablets
Specified dose of HS-10374-matched placebo tablets administered orally QD on specified days
Locations (1)
Huashan Hospital affiliated to Fudan University
Shanghai, Shanghai Municipality, China